For the year ending 2025-12-31, EVH had $2,200K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Loss before preferred dividends and accretion of series a preferred stock including excise tax | -534,510 |
| Change in fair value of contingent consideration | 6,495 |
| (gain) loss on disposal of non-strategic assets | 14,867 |
| (gain) loss from equity method investees | 365 |
| Extinguishment of series a preferred stock and other refinancing fees | 15,000 |
| Loss on option exercise | -52,544 |
| Depreciation and amortization expenses | 115,851 |
| Stock-based compensation expense | 39,739 |
| Deferred tax benefit | -2,982 |
| Amortization of contract cost assets | 6,794 |
| Amortization of deferred financing costs | 7,804 |
| Goodwill impairment | 398,000 |
| Loss on extinguishment/repayment of debt, net | -3,483 |
| Right-of-use asset impairment | 0 |
| Loss on lease termination | -676 |
| Change in tax receivables agreement liability | -804 |
| Right-of-use operating assets | -1,761 |
| Other current operating cash inflows (outflows), net | 0 |
| Accounts receivable, net and contract assets | -73,703 |
| Prepaid expenses and other current and non-current assets | -4,988 |
| Contract cost assets | 6,953 |
| Accounts payable | 6,639 |
| Accrued liabilities | 2,957 |
| Operating lease liabilities | -33,201 |
| Accrued compensation and employee benefits | 17,268 |
| Deferred revenue | -1,304 |
| Reserve for claims and performance-based arrangements | -126,509 |
| Other long-term liabilities | 5,028 |
| Net cash and restricted cash provided by operating activities | 38,843 |
| Cash paid for asset acquisitions and business combinations | 57,443 |
| Proceeds from disposal of non-strategic assets | 91,312 |
| Return of equity method investments | 986 |
| Purchases of investments and contributions to equity method investees | 1,000 |
| Investments in internal-use software and purchases of property and equipment | 34,088 |
| Net cash and restricted cash used in investing activities | -233 |
| Changes in working capital balances related to claims processing | 42,888 |
| Payment of contingent consideration | 1,750 |
| Proceeds from stock option exercises | 0 |
| Proceeds from issuance of preferred stock, net of offering costs | 0 |
| Proceeds from issuance of long-term debt, net of offering costs | -408,047 |
| Repayment of debt | 342,984 |
| Repurchase of common stock | 39,996 |
| Payment of preferred dividends | 11,127 |
| Taxes withheld and paid for vesting of equity awards | 5,226 |
| Net cash and restricted cash (used in) provided by financing activities | -35,924 |
| Effect of exchange rate on cash and cash equivalents and restricted cash | -486 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 2,200 |
| Cash and cash equivalents and restricted cash as of beginning-of-period | 178,496 |
| Cash and cash equivalents and restricted cash as of end-of-period | 180,696 |
Evolent Health, Inc. (EVH)
Evolent Health, Inc. (EVH)